PDCD1 and nonpapillary renal cell carcinoma: The emergence of immune checkpoint inhibitors, such as nivolumab (anti-PD-1), has brought new hope for the treatment of ccRCC patients, but the problem of a low response rate still limits the progress of ccRCC treatment (Au et al., 2021).